ALX Oncology Holdings Inc. ALXO
Set alert
As of Nov 2, 3:16 PM ET
- YTD
- +23.89%
- 1 year
- -9.09%
- Open
- 1.23
- Prev close
- 1.22
- Mkt cap
- 193.59M
- Vol
- 1.19M
- Avg vol
- 1.27M
- EPS
- -1.13
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.20
- High
- 1.42
- Forward P/E
- -0.68
- Beta
- 1.04
- Short ratio
- 8.58
- Inst. own
- 88.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.50
- 200-d avg
- 6.33
- 1y target
- 7.67
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.58; estimate -0.78; surprise 25.64%
- Nov 12, 2024Rating: Cantor Fitzgerald · — → Overweight
- Dec 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 18, 2024Rating: Cantor Fitzgerald · Overweight → Overweight
- Dec 19, 2024Downgrade: Jefferies · Buy → Hold
Signals (68)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| RSI: Oversold | Jun 16, 2026 | 4 months ago |
| RSI: Oversold | Jun 10, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 5 months ago |
| SMA: Bearish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 25, 2026 | 8 months ago |
| RSI: Overbought | Feb 19, 2026 | 8 months ago |
| RSI: Overbought | Feb 4, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 24, 2025 | 10 months ago |
| SMA: Bearish | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| RSI: Overbought | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| RSI: Overbought | Aug 21, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| RSI: Overbought | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 17, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 20, 2025 | 1 year ago |
| SMA: Bearish | Jan 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 7, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 27, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
Key statistics
- Market cap
- 96.52M
- Enterprise value
- -45.77M
- Trailing P/E
- 0.00
- Forward P/E
- -0.68
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- EPS (TTM)
- -2.97
- Beta
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -74.55M
- Total cash
- 148.57M
- Total debt
- 17.36M
- Return on equity
- -98.94%
- Shares outstanding
- 52.74M
- Short % of float
- 23.56%
- 50-day average
- 1.50
- 200-day average
- 6.33
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 7.67
- Target (high)
- 25.00
- Strong buy2
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.38766.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.78 | -0.58 | +0.20 | +25.64% |
| Aug 8, 2024 | Jun 1, 2024 | -0.77 | -0.76 | +0.01 | +1.30% |
| Aug 8, 2024 | Jun 1, 2024 | -0.77 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.87 | -0.71 | +0.16 | +18.39% |
| May 9, 2024 | Mar 1, 2024 | -0.87 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.84 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Jefferies | down | Buy | Hold |
| Dec 18, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 16, 2024 | UBS | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alxoncology.com
News
- 12 Health Care Stocks Moving In Friday's Intraday Session
- ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
- 7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc.
- ALX Oncology to Present at Upcoming Investor Conferences in September
- 5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO
- Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
- ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
- ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Your note
Sign in to keep a note on ALXO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARCIA PETER S | Chief Financial Officer | Purchase | Jun 12, 2024 | 122,348 |
| HEMRAJANI REKHA | Director | Purchase | Dec 1, 2024 | 33,000 |
| LETTMANN JASON | Chief Executive Officer | Purchase | Mar 13, 2024 | 171,620 |
| PINTO SHELLY | Officer | Sale | Aug 13, 2024 | 91,549 |
| PONS JAUME | President | Sale | Aug 13, 2024 | 591,510 |
| RANDOLPH SOPHIA | Officer | Sale | Aug 13, 2024 | 325,711 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| venBio Partners LLC | 18.39% | 9,699,925 | 17.75M | Sep 29, 2024 |
| FMR, LLC | 11.12% | 5,865,106 | 10.73M | Sep 29, 2024 |
| Tang Capital Management, LLC | 7.97% | 4,204,735 | 7.69M | Sep 29, 2024 |
| Vivo Capital, LLC | 7.65% | 4,034,522 | 7.38M | Sep 29, 2024 |
| Redmile Group, LLC | 7.27% | 3,836,576 | 7.02M | Sep 29, 2024 |
| Blackrock Inc. | 4.93% | 2,601,776 | 4.76M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 3.20% | 1,689,620 | 3.09M | Aug 30, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 2.00% | 1,057,220 | 1.93M | Aug 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.87% | 984,586 | 1.80M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.64% | 867,199 | 1.59M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.58% | 835,504 | 1.53M | Oct 30, 2024 |
| Fidelity Small Cap Growth K6 Fund | 1.18% | 621,497 | 1.14M | Aug 30, 2024 |